DDInter875 DDInter1643
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms.
Sarilumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Sarilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Sarilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Sarilumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Sarilumab {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Sarilumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Sarilumab may lead to a major life threatening interaction when taken with Cladribine
Sarilumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live